MedTrace Logo

Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosis

NCT04159610 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-12-24

No results posted yet for this study

Summary

The aim of this study is to investigate the safety, tolerability and efficacy of 1% GPB Cream compared to Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use under maximum use conditions.

Conditions

  • Primary Axillary Hyperhidrosis

Interventions

DRUG

WO3970

Application of cream to each axilla

DRUG

Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use

Qbrexza should be applied to the clean, dry, intact skin, of your underarm areas only

Sponsors & Collaborators

  • Therapeutics, Inc.

    collaborator INDUSTRY

  • Dr. August Wolff GmbH & Co. KG Arzneimittel

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-31
Primary Completion
2020-10-31
Completion
2020-10-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04159610 on ClinicalTrials.gov